Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays

Abstract

Phosphorylated tau (p-tau)217 cutpoints for detection of amyloid pathology were established. A two-cutpoint approach exhibited the best performance for clinical laboratory use. p-tau217 assays differed in the percentage of results categorized as intermediate.